Haemonetics Co. (NYSE:HAE) Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC raised its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 62.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,329 shares of the medical instruments supplier's stock after purchasing an additional 8,626 shares during the quarter. Intech Investment Management LLC's holdings in Haemonetics were worth $1,795,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in Haemonetics in the second quarter valued at $39,000. Daiwa Securities Group Inc. purchased a new stake in Haemonetics in the second quarter valued at $82,000. Canada Pension Plan Investment Board purchased a new stake in Haemonetics in the second quarter valued at $83,000. Nisa Investment Advisors LLC boosted its stake in shares of Haemonetics by 124.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 632 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Haemonetics during the 2nd quarter worth about $140,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HAE. CL King began coverage on shares of Haemonetics in a research note on Friday, September 13th. They set a "buy" rating and a $116.00 target price on the stock. Raymond James raised shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 target price on the stock in a research note on Friday, November 8th. Citigroup lowered their target price on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a research note on Thursday, August 22nd. BTIG Research began coverage on shares of Haemonetics in a research note on Tuesday, September 10th. They set a "buy" rating and a $112.00 target price on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $112.00 target price on shares of Haemonetics in a research note on Friday, November 15th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $107.88.

Haemonetics Price Performance

Haemonetics stock traded up $0.10 during midday trading on Tuesday, reaching $88.56. The company had a trading volume of 602,146 shares, compared to its average volume of 556,577. The company has a market capitalization of $4.45 billion, a P/E ratio of 36.75, a P/E/G ratio of 1.33 and a beta of 0.32. Haemonetics Co. has a 12-month low of $70.25 and a 12-month high of $97.97. The firm's fifty day simple moving average is $79.23 and its 200-day simple moving average is $82.24. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating analysts' consensus estimates of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics's quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.99 EPS. As a group, equities analysts anticipate that Haemonetics Co. will post 4.59 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.